The global drug of abuse testing market was valued at $4,407.8 million in 2015, and it is expected to grow ata CAGR of 9.6% during the period 2016 – 2022. The drug of abuse testing market is growing, due to increased availability of drugs, increasing consumption of drugs,and increasing road accidents. In addition, the workplace drug of abuse testing is also increasing, in order to provide safer working environment, increase productivity and decrease absentism at work.
Among the different products for drug of abuse testing, the consumable segment is expected to witness the faster growth during the forecast period. Among the sample types,the urine testing segmentheld the largest sharein the global market in 2015, and it is expected to witness the fastest growth during the forecast period. Among the various end-users, the hospital segment held the largest share in the global market in 2015.
The use of illicit drugs is increasing globally, due to which, the demand for drug of abuse testing is expected to increase. In addition, the technological advancement in drug of abuse testing is leading to their increased acceptances in various settings. The aim of technological advancements in drug of abuse testing is to detect low concentration of drugs, and reduce timeconsumption.
Some of the key companies operating in the global drug of abuse testing market include Siemens HealthcareAG, F. Hoffmann-La Roche Ltd., Millipore Sigma, Danaher Corporation,Alere Inc., Abbott Laboratories, Drägerwerk AG & Co. KGAA, Express Diagnostics Int’l, Inc. Shimadzu Corporation, Waters Corporation, bioMérieux SA, Quest Diagnostics Inc., Laboratory Corporation of America Holdings, Randox Laboratories Ltd., Psychemedics Corporation, Sonic Healthcare Ltd.,Thermo Fisher Scientific Inc., and Bio-Rad Laboratories.
News Courtesy: P&S Market Research